OpenAlex
PricingAboutJobs
Log inGet started
Work

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure

HTML

Year: 2015
Type: article
Source: Gene Therapy
DOI: 10.1038/gt.2015.109
Authors: B Greenberg, J Butler, G M Felker, P Ponikowski, A A Voors, J M Pogoda, R Provost, J Guerrero, R J Hajjar, K M Zsebo
Institutions: University of California San Diego, Stony Brook University, Duke University, Wroclaw Medical University, University of Groningen, Celladon Corporation (United States), Icahn School of Medicine at Mount Sinai
Language: English

Topic: Virus-based gene therapy research
Subfield: Genetics
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: neutralizing antibodies, advanced heart failure, immunosuppression, cross-reactivity, AAV2, minipigs, seroprevalence, age-related antibody titers, inclusion and exclusion criteria
SDG: Good health and well-being

Open Access status: green

Funders: Celladon Corporation, Fondation Leducq, National Institutes of Health, National Heart, Lung, and Blood Institute
Awards: Targeting Abnormal Calcium Cycling Using Novel Gene Therapy Vectors, TRIP: Targeted Gene Therapy for the Treatment of Heart Failure, SUMO1 and SERCA2a Function, Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
OpenAlex ID: W2220787769
FWCI: 5.744
Cites: 23
Cited by: 121
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security